Seoul Pharma Co., Ltd (KOSDAQ:018680)

Seoul Pharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	5,663	7,540	6,574	11,728	13,820	15,057
Short-Term Investments	-	-	-	-	-	3.18
Trading Asset Securities	979.26	-	3,090	-	-	-
Cash & Short-Term Investments	6,642	7,540	9,664	11,728	13,820	15,061
Cash Growth	-38.39%	-21.98%	-17.61%	-15.14%	-8.24%	96.47%
Accounts Receivable	8,801	9,127	5,041	4,925	4,437	3,157
Other Receivables	2,942	338.72	89.52	65.46	33.23	16.72
Receivables	11,743	9,465	5,131	4,990	4,470	3,238
Inventory	12,479	12,104	10,696	9,198	6,466	7,454
Prepaid Expenses	26.43	28.18	28.62	28.89	26.42	25.56
Other Current Assets	1,558	3,120	90.13	66.38	30.4	154.65
Total Current Assets	32,448	32,257	25,609	26,012	24,814	25,933
Property, Plant & Equipment	33,402	33,855	31,330	30,676	34,055	35,476
Long-Term Investments	3	3	999.4	3	3	3
Other Intangible Assets	802.94	809.45	841.72	881.35	865.11	1,100
Long-Term Deferred Tax Assets	4,176	4,142	4,013	4,386	2,070	2,108
Long-Term Deferred Charges	-	-	-	-	-	8.2
Other Long-Term Assets	556.87	552.8	512.48	470.08	443.34	460.15
Total Assets	71,389	71,620	63,305	62,428	62,250	65,087
Accounts Payable	2,916	2,420	2,831	2,995	1,975	801.97
Accrued Expenses	5,247	5,250	4,309	3,933	3,547	2,548
Short-Term Debt	3,000	3,000	-	4,000	18,049	2,000
Current Portion of Long-Term Debt	-	-	10,000	-	-	10,000
Current Portion of Leases	667.07	666.14	485.16	466.11	463.09	470.07
Current Income Taxes Payable	138.49	155.91	-	-	-	146.77
Other Current Liabilities	2,031	2,649	2,907	2,497	4,770	2,479
Total Current Liabilities	14,000	14,141	20,532	13,891	28,805	18,447
Long-Term Debt	10,000	10,000	-	10,000	10,000	13,354
Long-Term Leases	2,293	2,460	470.73	481.28	871.11	1,317
Other Long-Term Liabilities	1,228	1,149	655.68	216.9	220.46	430.42
Total Liabilities	31,381	31,448	24,741	27,006	43,292	36,235
Common Stock	5,830	5,830	5,830	5,830	4,262	4,262
Additional Paid-In Capital	29,592	29,592	29,592	47,247	33,675	33,675
Retained Earnings	4,586	4,750	3,142	-19,414	-20,739	-10,844
Comprehensive Income & Other	-	0	-	1,760	1,760	1,760
Shareholders' Equity	40,008	40,172	38,564	35,422	18,958	28,852
Total Liabilities & Equity	71,389	71,620	63,305	62,428	62,250	65,087
Total Debt	15,960	16,126	10,956	14,947	29,383	27,141
Net Cash (Debt)	-9,318	-8,586	-1,292	-3,219	-15,563	-12,080
Net Cash Per Share	-799.20	-736.44	-110.83	-358.47	-1825.71	-1421.49
Filing Date Shares Outstanding	11.66	11.66	11.66	11.66	8.52	8.52
Total Common Shares Outstanding	11.66	11.66	11.66	11.66	8.52	8.52
Working Capital	18,448	18,116	5,077	12,121	-3,991	7,486
Book Value Per Share	3431.40	3445.48	3307.58	3038.06	2223.90	3384.64
Tangible Book Value	39,205	39,363	37,722	34,540	18,093	27,753
Tangible Book Value Per Share	3362.53	3376.06	3235.39	2962.47	2122.41	3255.65
Land	-	5,156	5,156	5,156	5,156	5,156
Buildings	-	27,916	27,445	27,334	27,334	27,334
Machinery	-	25,420	25,747	24,517	23,201	22,508
Construction In Progress	-	-	40.5	132.85	390.9	150

Source: S&P Global Market Intelligence. Standard template. Financial Sources.